Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids

References

• Donnez J, Dolmans MM. Uterine fibroid management: from the present to the future. Hum Reprod Update. 2016 Nov;22(6):665–686.
   PubMed Web of Science ®Google Scholar
• Bulun SE. Tissue stem cells and uterine physiology and pathology. Semin Reprod Med. 2015 Sep;33(5):313–314.
   PubMed Web of Science ®Google Scholar
• McWilliams MM, Chennathukuzhi VM. Recent advances in uterine fibroid etiology. Semin Reprod Med. 2017 Mar;35(2):181–189.
   PubMed Web of Science ®Google Scholar
• Freytag D, Günther V, Maass N, et al. Uterine Fibroids and Infertility. Diagnostics (Basel). 2021;11(8):1455.
   PubMedGoogle Scholar
• Malone LJ. Myomectomy: recurrence after removal of solitary and multiple myomas. Obstet Gynecol. 1969 Aug;34(2):200–203.
   PubMed Web of Science ®Google Scholar
• Bulman JC, Ascher SM, Spies JB. Current concepts in uterine fibroid embolization. Radiographics. 2012 Oct;32(6):1735–1750.
   PubMed Web of Science ®Google Scholar
• Spies JB, Myers ER, Worthington-Kirsch R, et al. The FIBROID registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol. 2005 Dec;106(6):1309–1318.
   PubMed Web of Science ®Google Scholar
• Hutchins FLsJr., Worthington-Kirsch R, Berkowitz RP. Selective uterine artery embolization as primary treatment for symptomatic leiomyomata uteri. J Am Assoc Gynecol Laparosc. 1999 Aug;6(3):279–284.
   PubMedGoogle Scholar
• Domingo S, Perales-Puchalt A, Soler I, et al. Clinical outcome, fertility and uterine artery Doppler scans in women with obstetric bilateral internal iliac artery ligation or embolisation. J Obstet Gynaecol. 2013 Oct;33(7):701–704.
   PubMedGoogle Scholar
• Gupta JK, Sinha A, Lumsden MA, et al. Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database Syst Rev. 2014 Dec;26(12):CD005073.
   Google Scholar
• Qin J, Yang T, Kong F, et al. Oral contraceptive use and uterine leiomyoma risk: a meta-analysis based on cohort and case-control studies. Arch Gynecol Obstet. 2013 Jul;288(1):139–148.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. Bjog. 2002 Oct;109(10):1097–1108.
   PubMed Web of Science ®Google Scholar
• Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 1992 Feb;166(2):746–751.
   PubMed Web of Science ®Google Scholar
• Moroni RM, Martins WP, Ferriani RA, et al. Add-back therapy with GnRH analogues for uterine fibroids. Cochrane Database Syst Rev. 2015 Mar;20(3):CD010854.
   Google Scholar
• Barra F, Scala C, Ferrero S. Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain. Drugs Today (Barc). 2019 Apr;55(4):237–246.
   PubMed Web of Science ®Google Scholar
• Barra F, Seca M, Della Corte L, et al. Relugolix for the treatment of uterine fibroids. Drugs Today (Barc). 2019 Aug;55(8):503–512.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):107–116.
   PubMed Web of Science ®Google Scholar
• Bristot M, Grande AJ, Laura M, et al. Efficacy of ulipristal acetate for uterine fibroids an updated meta-analysis. 2021 Mar 28.
   Google Scholar
• Vitale SG, Ferrero S, Caruso S, et al. Ulipristal acetate before hysteroscopic myomectomy: a systematic review. Obstet Gynecol Surv. 2020 Feb;75(2):127–135.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Scala C, Vellone VG, et al. Preoperative treatment with ulipristal acetate before outpatient hysteroscopic myomectomy. Gynecol Obstet Invest. 2020;85(2):178–183.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ulipristal acetate for uterine fibroids: EMA recommends restricting use. 2021. [cited 2022 Mar 1]. Available from: https://www.ema.europa.eu/en/documents/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-ulipristal-acetate-uterine-fibroids_en.pdf
   Google Scholar
• Ciebiera M, Vitale SG, Ferrero S, et al. Vilaprisan, a new selective progesterone receptor modulator in uterine fibroid pharmacotherapy-will it really be a breakthrough? Curr Pharm Des. 2020;26(3):300–309.
   PubMed Web of Science ®Google Scholar
• Deng L, Wu T, Chen XY, et al. Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. Cochrane Database Syst Rev. 2012 Oct 17;10:CD005287.
   PubMedGoogle Scholar
• van Leeuwen FE, Benraadt J, Coebergh JW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994 Feb 19;343(8895):448–452.
   PubMed Web of Science ®Google Scholar
• Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997 Mar;138(3):863–870.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Reierstad S, Demura M, et al. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab. 2009 May;94(5):1752–1756.
   PubMed Web of Science ®Google Scholar
• Hilario SG, Bozzini N, Borsari R, et al. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. Fertil Steril. 2009 Jan;91(1):240–243.
   PubMed Web of Science ®Google Scholar
• Song H, Lu D, Navaratnam K, et al. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013(10). doi:10.1002/14651858.CD009505.pub2.
   Web of Science ®Google Scholar
• McGavigan CJ, Cameron IT. The Mirena levonorgestrel system. Drugs Today (Barc). 2003 Dec;39(12):973–984.
   PubMed Web of Science ®Google Scholar
• Ortiz ME, Croxatto HB. The mode of action of IUDs. Contraception. 1987 Jul;36(1):37–53.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018 Jul;5:1–17.
   Google Scholar
• Barra F, Grandi G, Tantari M, et al. A comprehensive review of hormonal and biological therapies for endometriosis: latest developments. Expert Opin Biol Ther. 2019 Apr;19(4):343–360.
   PubMed Web of Science ®Google Scholar
• Beatty MN, Blumenthal PD. The levonorgestrel-releasing intrauterine system: safety, efficacy, and patient acceptability. Ther Clin Risk Manag. 2009 Jun;5(3):561–574.
   PubMedGoogle Scholar
• Zapata LB, Whiteman MK, Tepper NK, et al. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception. 2010 Jul;82(1):41–55.
   PubMed Web of Science ®Google Scholar
• Jiang W, Shen Q, Chen M, et al. Levonorgestrel-releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: a systematic review. Steroids. 2014 Aug;86:69–78.
   PubMed Web of Science ®Google Scholar
• Jamieson A, Slutsker L, Inglis GC, et al. Glucocorticoid-suppressible hyperaldosteronism: effects of crossover site and parental origin of chimaeric gene on phenotypic expression. Clin Sci (Lond). 1995 May;88(5):563–570.
   PubMed Web of Science ®Google Scholar
• Zalel Y, Gamzu R, Shulman A, et al. The progestative effect of the levonorgestrel-releasing intrauterine system–when does it manifest? Contraception. 2003 Jun;67(6):473–476.
   PubMed Web of Science ®Google Scholar
• Silverberg SG, Haukkamaa M, Arko H, et al. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol. 1986;5(3):235–241.
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a d-norgestrel-releasing intrauterine device. Fertil Steril. 1978 Apr;29(4):397–401.
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Lahteenmaki PL, Luukkainen T, et al. Sustained intrauterine release of levonorgestrel over five years. Fertil Steril. 1986 Jun;45(6):805–807.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005 Aug;8(Suppl 1):3–63.
   PubMed Web of Science ®Google Scholar
• Kailasam C, Cahill D. Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system. Patient Prefer Adherence. 2008 Feb 2;2:293–302.
   PubMedGoogle Scholar
• Group ECW. Intrauterine devices and intrauterine systems. Hum Reprod Update. 2008;14(3):197–208.
   PubMed Web of Science ®Google Scholar
• Lähteenmäki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids. 2000;65(10–11):693–697.
   PubMed Web of Science ®Google Scholar
• Nilsson CG, Haukkamaa M, Vierola H, et al. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf). 1982 Dec;17(6):529–536.
   PubMed Web of Science ®Google Scholar
• Kurunmäki H, Toivonen J, Lähteenmäki P, et al. Intracervical release of levonorgestrel for contraception. Contraception. 1981 May 1;23(5):473–485.
   PubMed Web of Science ®Google Scholar
• Ld Hteenmd Ki P, Nilsson CG. Plasma concentrations of ethinylestradiol and D-norgestrel during two immediate postabortal oral contraceptive cycles. Contraception. 1978;17(1):9–17.
   PubMed Web of Science ®Google Scholar
• Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med. 1990 Apr;22(2):85–90.
   PubMed Web of Science ®Google Scholar
• Kaunitz AM. Progestin-releasing intrauterine systems and leiomyoma. Contraception. 2007;75(6):S130–S133.
   PubMed Web of Science ®Google Scholar
• Juchem M, Pollow K. Binding of oral contraceptive progestogens to serum proteins and cytoplasmic receptor. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 2):2171–2183.
   PubMed Web of Science ®Google Scholar
• Phillips A, Hahn DW, McGuire JL. Relative binding affinity of norgestimate and other progestins for human sex hormone-binding globulin. Steroids. 1990 Aug 1;55(8):373–375.
   PubMed Web of Science ®Google Scholar
• Moreno I, Quinones L, Catalan J, et al. Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study. Biomedica. 2012 Oct-Dec;32(4):570–577.
   PubMed Web of Science ®Google Scholar
• Pavlovich SV, Volkov NI, Burlev VA. Proliferative activity and level of steroid hormone receptors in the myometrium and myoma nodes in different phases of menstrual cycle. Bull Exp Biol Med. 2003 Oct;136(4):396–398.
   PubMed Web of Science ®Google Scholar
• Xu Q, Qiu L, Zhu L, et al. Levonorgestrel inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Contraception. 2010 Sep;82(3):301–308.
   PubMed Web of Science ®Google Scholar
• Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception. 1994 Jan;49(1):56–72.
   PubMed Web of Science ®Google Scholar
• Magon N. Gonadotropin releasing hormone agonists: expanding vistas. Indian J Endocrinol Metab. 2011 Oct;15(4):261–267.
   PubMedGoogle Scholar
• Padula AM. GnRH analogues–agonists and antagonists. Anim Reprod Sci. 2005 Aug;88(1–2):115–126.
   PubMed Web of Science ®Google Scholar
• Lethaby AE, Vollenhoven B, Sowter MC. Efficacy of pre-operative gonadotropin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. Obstet Gynecol Surv. 2003;58(5):323–324.
   Google Scholar
• Dou Q, Zhao Y, Tarnuzzer RW, et al. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab. 1996 Sep;81(9):3222–3230.
   PubMed Web of Science ®Google Scholar
• Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995 Jan;172(1 Pt 1):14–18.
   PubMed Web of Science ®Google Scholar
• Rein MS, Friedman AJ, Pandian MR, et al. The secretion of insulin-like growth factors I and II by explant cultures of fibroids and myometrium from women treated with a gonadotropin-releasing hormone agonist. Obstet Gynecol. 1990 Sep;76(3 Pt 1):388–394.
   PubMed Web of Science ®Google Scholar
• Lumsden MA, West CP, Bramley T, et al. The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist. Br J Obstet Gynaecol. 1988 Dec;95(12):1299–1304.
   PubMedGoogle Scholar
• Shozu M, Sumitani H, Segawa T, et al. Inhibition of in situ expression of aromatase P450 in leiomyoma of the uterus by leuprorelin acetate. J Clin Endocrinol Metab. 2001 Nov;86(11):5405–5411.
   PubMed Web of Science ®Google Scholar
• Lethaby A, Puscasiu L, Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst Rev. 2017 Nov 15;11:CD000547.
   PubMedGoogle Scholar
• Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril. 1990 Sep;54(3):419–427. Lupron Study Group
   PubMed Web of Science ®Google Scholar
• Franke HR, van de Weijer PH, Pennings TM, et al. Gonadotropin-releasing hormone agonist plus “add-back” hormone replacement therapy for treatment of endometriosis: a prospective, randomized, placebo-controlled, double-blind trial. Fertil Steril. 2000 Sep;74(3):534–539.
   PubMed Web of Science ®Google Scholar
• Matsuo H. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist treatment for endometriosis. Fertil Steril. 2004 Jan;81(1):149–153.
   PubMed Web of Science ®Google Scholar
• Sagsveen M, Farmer JE, Prentice A, et al. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev. 2003; (4):CD001297. DOI:10.1002/14651858.CD001297.
   PubMedGoogle Scholar
• LUPRON DEPOT®3.75 mg. 2022 Mar 1. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019943s032,020011s039lbl.pdf
   Google Scholar
• LUPRON DEPOT®11.25 mg. 2022 Mar 1. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020708s033lbl.pdf
   Google Scholar
• Wilson AC, Meethal SV, Bowen RL, et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007 Nov;16(11):1851–1863.
   PubMed Web of Science ®Google Scholar
• Gerhard I, Schindler AE, Buhler K, et al. Treatment of endometriosis with leuprorelin acetate depot: a German multicentre study. Clin Ther. 1992;14(Suppl A):3–16.
   PubMedGoogle Scholar
• Irahara M, Uemura H, Yasui T, et al. Efficacy of every-other-day administration of conjugated equine estrogen and medroxyprogesterone acetate on gonadotropin-releasing hormone agonists treatment in women with endometriosis. Gynecol Obstet Invest. 2001;52(4):217–222.
   PubMed Web of Science ®Google Scholar
• Decapeptyl®(Triptorelin Acetate Injection) 2022 February 23. Available from: https://www.ferring.ca/media/1016/decapeptyl-pm-english.pdf
   Google Scholar
• Barron JL, Millar RP, Searle D. Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. J Clin Endocrinol Metab. 1982 Jun;54(6):1169–1173.
   PubMed Web of Science ®Google Scholar
• Roberti Maggiore U L, Scala C, Remorgida V, et al. Triptorelin for the treatment of endometriosis. Expert Opin Pharmacother. 2014 Jun;15(8):1153–1179.
   PubMed Web of Science ®Google Scholar
• Tafi E, Scala C, Leone Roberti Maggiore U, et al. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. Expert Opin Drug Saf. 2015 Jun;14(6):965–977.
   PubMed Web of Science ®Google Scholar
• Xu Q, Takekida S, Ohara N, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5’-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab. 2005 Feb;90(2):953–961.
   PubMed Web of Science ®Google Scholar
• Courtoy GE, Donnez J, Marbaix E, et al. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertil Steril. 2015 Aug;104(2):426–34 e1.
   PubMed Web of Science ®Google Scholar
• Xu Q, Ohara N, Liu J, et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod. 2008 Mar;14(3):181–191.
   PubMed Web of Science ®Google Scholar
• Shin SJ, Kim J, Lee S, et al. Ulipristal acetate induces cell cycle delay and remodeling of extracellular matrix. Int J Mol Med. 2018 Oct;42(4):1857–1864.
   PubMed Web of Science ®Google Scholar
• Cox J, Malik M, Britten J, et al. Ulipristal acetate and extracellular matrix production in human leiomyomas in vivo: a laboratory analysis of a randomized placebo controlled trial. Reprod Sci. 2018 Feb;25(2):198–206.
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P, et al. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2007 Sep;92(9):3582–3589.
   PubMed Web of Science ®Google Scholar
• Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014 Jun;101(6):1565–73 e1–18.
   Web of Science ®Google Scholar
• Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012 Feb 2;366(5):409–420.
   PubMed Web of Science ®Google Scholar
• Talaulikar VS, Manyonda IT. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids. Adv Ther. 2012 Aug;29(8):655–663.
   PubMed Web of Science ®Google Scholar
• Orihuela P. Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids. Curr Opin Invest Drugs. 2007 Nov 1;8(10):859–866.
   PubMedGoogle Scholar
• Esmya ® (Ulipristal Acetate). 2022 Mar 1. Available from: https://www.ema.europa.eu/en/documents/product-information/esmya-epar-product-information_en.pdf
   Google Scholar
• Blithe DL, Nieman LK, Blye RP, et al. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003 Nov;68(10–13):1013–1017.
   PubMed Web of Science ®Google Scholar
• Pohl O, Zobrist RH, Gotteland JP. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids. Reprod Sci. 2015 Apr;22(4):476–483.
   PubMed Web of Science ®Google Scholar
• Pohl O, Kendrick J, Gotteland J-P. Metabolic disposition of [14C] ulipristal acetate in healthy premenopausal women. J Bioequivalence Bioavailability. 2013;06(12):177–184.
   Google Scholar
• Melis GB, Piras B, Marotto MF, et al. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment. Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):901–908.
   PubMed Web of Science ®Google Scholar
• Pohl O, Osterloh I, Lecomte V, et al. Changes in gastric pH and in pharmacokinetics of ulipristal acetate - a drug-drug interaction study using the proton pump inhibitor esomeprazole. Int J Clin Pharmacol Ther. 2013 Jan;51(1):26–33.
   PubMed Web of Science ®Google Scholar
• Donnez J, Tomaszewski J, Vazquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012 Feb 2;366(5):421–432.
   PubMed Web of Science ®Google Scholar
• Donnez J, Vázquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate ☆. Fertil Steril. 2014 Jun;101(6):1565–73.e1–18.
   Web of Science ®Google Scholar
• Ali M, Al-Hendy A. Uterine fibroid therapy: the pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):887–889.
   PubMed Web of Science ®Google Scholar
• Bradley LD, Singh SS, Simon J, et al. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study. Fertil Steril. 2019 Feb;111(2):240–248.
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Heikinheimo O, Zatik J, et al. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the phase 2b randomized controlled trial ASTEROID 2. Eur J Obstet Gynecol Reprod Biol. 2020 Sep;252:7–14.
   PubMed Web of Science ®Google Scholar
• Schutt B, Kaiser A, Schultze-Mosgau MH, et al. Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women. Hum Reprod. 2016 Aug;31(8):1703–1712.
   PubMed Web of Science ®Google Scholar
• Seitz C, Bumbuliene Z, Costa AR, et al. Rationale and design of ASTEROID 2, a randomized, placebo- and active comparator-controlled study to assess the efficacy and safety of vilaprisan in patients with uterine fibroids. Contemp Clin Trials. 2017 Apr;55:56–62.
   PubMed Web of Science ®Google Scholar
• Melis GB, Neri M, Piras B, et al. Vilaprisan for treating uterine fibroids. Expert Opin Investig Drugs. 2018 May;27(5):497–505.
   PubMed Web of Science ®Google Scholar
• Schutt B, Schultze-Mosgau MH, Draeger C, et al. Effect of the novel selective progesterone receptor modulator vilaprisan on ovarian activity in healthy women. J Clin Pharmacol. 2018 Feb;58(2):228–239.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau MH, Hochel J, Prien O, et al. Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet. 2018 Aug;57(8):1001–1015.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau M-H, Ploeger BA, Frei M, et al. Clinical pharmacokinetics and pharmacodynamics of the selective progesterone receptor modulator vilaprisan: a comprehensive overview. Clin Pharmacokinet. 2022 Jan 1;61(1):1–16.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau MH, Kaiser A, Zollmann FS. Effect of food intake on the pharmacokinetics of the selective progesterone receptor modulator vilaprisan: a randomized clinical study in healthy postmenopausal women. Clin Pharmacol Drug Dev. 2021 Jun;10(6):675–680.
   PubMed Web of Science ®Google Scholar
• Sutter G, Frei M, Schultze-Mosgau MH, et al. Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation. Br J Clin Pharmacol. 2022 Feb;88(2):734–741.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau MH, Schuett B, Hafner FT, et al. Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women. Int J Clin Pharmacol Ther. 2017 Jan;55(1):16–24.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay N, Kanacher T, Casjens M, et al. CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. Br J Clin Pharmacol. 2018 Dec;84(12):2857–2866.
   PubMed Web of Science ®Google Scholar
• Chattopadhyay N, Riecke K, Ligges S, et al. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: an open-label, single-dose, parallel-group study. Br J Clin Pharmacol. 2019 Sep;85(9):2011–2021.
   PubMed Web of Science ®Google Scholar
• Schultze-Mosgau MH, Lasseter KC, Marbury T, et al. Pharmacokinetics and safety of the novel selective progesterone receptor modulator vilaprisan in participants with renal impairment. J Clin Pharmacol. 2020 Aug;60(8):1030–1038.
   PubMed Web of Science ®Google Scholar
• Ezzati M, Carr BR. Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain. Womens Health (Lond). 2015 Jan;11(1):19–28.
   PubMedGoogle Scholar
• Reichman D, Rosenwaks Z. GnRH antagonist-based protocols for in vitro fertilization. Methods Mol Biol. 2014;1154:289–304.
   PubMedGoogle Scholar
• Tarlatzis BC, Kolibianakis EM. GnRH agonists vs antagonists. Best Pract Res Clin Obstet Gynaecol. 2007 Feb;21(1):57–65.
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Vercellini P, Meschia M, et al. GnRH agonists before surgery for uterine leiomyomas. A review. J Reprod Med. 1996 Jun;41(6):415–421.
   PubMed Web of Science ®Google Scholar
• Sabry M, Al-Hendy A. Innovative oral treatments of uterine leiomyoma. Obstet Gynecol Int. 2012;2012:943635.
   PubMedGoogle Scholar
• Lamb YN. Elagolix: first Global Approval. Drugs. 2018 Sep;78(14):1501–1508.
   PubMed Web of Science ®Google Scholar
• Chen C, Wu D, Guo Z, et al. Discovery of sodium R-(+)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-[trifluoromethyl]benzyl)-4 -methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate (elagolix), a potent and orally available nonpeptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2008 Dec 11;51(23):7478–7485.
   PubMed Web of Science ®Google Scholar
• Oriahnn® (Printed Labelling). 2022 Mar 2. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213388Orig1s000lbl.pdf
   Google Scholar
• Shebley M, Polepally AR, Nader A, et al. Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmacokinet. 2020 Mar;59(3):297–309.
   PubMed Web of Science ®Google Scholar
• Winzenborg I, Nader A, Polepally AR, et al. Population pharmacokinetics of elagolix in healthy women and women with endometriosis. Clin Pharmacokinet. 2018 Oct;57(10):1295–1306.
   PubMed Web of Science ®Google Scholar
• Ng J, Chwalisz K, Carter DC, et al. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017 May 1;102(5):1683–1691.
   PubMed Web of Science ®Google Scholar
• Osuga Y, Enya K, Kudou K, et al. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women. Fertil Steril. 2019 Nov;112(5):922–929 e2.
   PubMed Web of Science ®Google Scholar
• Barra F, Vitale SG, Seca M, et al. The potential role of elagolix for treating uterine bleeding associated to uterine myomas. Expert Opin Pharmacother. 2020 Aug;21(12):1419–1430.
   PubMed Web of Science ®Google Scholar
• Ng J, Duan WR, Marbury T, et al. Elagolix pharmacokinetic profiles in women with renal or hepatic impairment. Clin Pharmacol Drug Dev. 2019 Nov;8(8):1053–1061.
   PubMed Web of Science ®Google Scholar
• Struthers RS, Nicholls AJ, Grundy J, et al. Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. J Clin Endocrinol Metab. 2009 Feb;94(2):545–551.
   PubMed Web of Science ®Google Scholar
• Nader A, Mostafa NM, Ali F, et al. Drug-drug interaction studies of elagolix with oral and transdermal low-dose hormonal add-back therapy. Clin Pharmacokinet. 2021 Jan;60(1):133–143.
   PubMed Web of Science ®Google Scholar
• Chiney MS, Ng J, Gibbs JP, et al. Quantitative assessment of elagolix enzyme-transporter interplay and drug-drug interactions using physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2020 May;59(5):617–627.
   PubMed Web of Science ®Google Scholar
• Schlaff WD, Ackerman RT, Al-Hendy A, et al. Elagolix for heavy menstrual bleeding in women with uterine fibroids. N Engl J Med. 2020 Jan 23;382(4):328–340.
   PubMed Web of Science ®Google Scholar
• Simon JA, Al-Hendy A, Archer DF, et al. Elagolix treatment for up to 12 months in women with heavy menstrual bleeding and uterine leiomyomas. Obstet Gynecol. 2020 Jun;135(6):1313–1326.
   PubMed Web of Science ®Google Scholar
• Carr BR, Stewart EA, Archer DF, et al. Elagolix alone or with add-back therapy in women with heavy menstrual bleeding and uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018 Nov;132(5):1252–1264.
   PubMed Web of Science ®Google Scholar
• Markham A. Relugolix: first Global Approval. Drugs. 2019 Apr;79(6):675–679.
   PubMed Web of Science ®Google Scholar
• Myfembree® (CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S)). 2022 March 2. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214846Orig1s000ClinPharmR.pdf
   Google Scholar
• Lukes A , Johnson B , Jones B, et al. Pharmacokinetics, pharmacodynamics, and safety of relugolix, a potent oral once-daily gonadotropin-releasing hormone (GnRH) receptor antagonist, as monotherapy and in combination with estradiol/norethindrone acetate add-back therapy. In: Human Reproduction, Vol. 32. Oxford (England): Oxford Univ Press Great Clarendon St; 2017. p. 267–268.
   Google Scholar
• MacLean DB, Shi H, Faessel HM, et al. Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab. 2015 Dec;100(12):4579–4587.
   PubMed Web of Science ®Google Scholar
• Al-Hendy A, Lukes AS, Poindexter ANs3rd, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021 Feb 18;384(7):630–642.
   PubMed Web of Science ®Google Scholar
• Pohl O, Marchand L, Bell D, et al. Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern. Reprod Sci. 2020 Apr;27(4):988–995.
   PubMed Web of Science ®Google Scholar
• Pohl O, Marchand L, Fawkes N, et al. Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: pharmacodynamics and Safety of OBE2109. J Clin Endocrinol Metab. 2018 Feb 1;103(2):497–504.
   PubMed Web of Science ®Google Scholar
• Evangelisti G, Ferrero S, Barra F. Linzagolix choline. Gonadotropin-releasing hormone, (GnRH) receptor antagonist, treatment of uterine fibroids, treatment of endometriosis. Drugs Future. 2021;46(11):871.
   Google Scholar
• Kissei Pharmaceutical Co. L. Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof. WO2007046392A1. 2017.
   Google Scholar
• 城一道 秀. Salt of fused heterocyclic derivative and crystal thereof. WO2011099507A1. 2011.
   Google Scholar
• Donnez J, Dolmans MM. Endometriosis and medical therapy: from progestogens to progesterone resistance to GnRH antagonists: a review. J Clin Med. 2021 Mar 5;10(5):1085.
   PubMed Web of Science ®Google Scholar
• Donnez J, Taylor HS, Taylor RN, et al. Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril. 2020 Jul;114(1):44–55.
   PubMed Web of Science ®Google Scholar
• Huber PA, Fraser ID, Marston SB. Location of smooth-muscle myosin and tropomyosin binding sites in the C-terminal 288 residues of human caldesmon. Biochem J. 1995 Dec 1;312(Pt 2):617–625.
   PubMedGoogle Scholar
• Taylor H, Donnez J, Taylor R, et al. Efficacy and safety of linzagolix on heavy menstrual bleeding (HMB) due to uterine fibroids (UF): results from a placebo-controlled, randomized, Phase 3 trial. Hum Reprod. 2020;35(Supplement_1):i1–i522.
   PubMedGoogle Scholar
• Donnez J, Dolmans MM. Fibroids and medical therapy: bridging the gap from selective progesterone receptor modulators to gonadotropin-releasing hormone antagonist. Fertil Steril. 2020 Oct;114(4):739–741.
   PubMed Web of Science ®Google Scholar
• Bradley LD, Marsh EE, Garner E. LINZAGOLIX MAY ADDRESS THE LONG-TERM TREATMENT NEEDS OF WOMEN WITH UTERINE FIBROIDS (UF) WHO HAVE CONTRAINDICATIONS TO HORMONAL ADD-BACK THERAPY (ABT): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS. Fertil Steril. 2020;114(3):e527.
   Web of Science ®Google Scholar
• Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003 Sep;86(3–5):225–230.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Robertson JF, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 2002 Nov 1;95(9):2006–2016.
   PubMed Web of Science ®Google Scholar
• U LRM, Scala C, Venturini PL, et al. Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study. Eur J Obstet Gynecol Reprod Biol. 2014 Oct;181:157–162.
   PubMed Web of Science ®Google Scholar
• Parsanezhad ME, Azmoon M, Alborzi S, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010 Jan;93(1):192–198.
   PubMed Web of Science ®Google Scholar
• Gurates B, Parmaksiz C, Kilic G, et al. Treatment of symptomatic uterine leiomyoma with letrozole. Reprod Biomed Online. 2008 Oct;17(4):569–574.
   PubMed Web of Science ®Google Scholar
• Sioufi A, Sandrenan N, Godbillon J, et al. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration. Biopharm Drug Dispos. 1997 Aug;18(6):489–497.
   PubMed Web of Science ®Google Scholar
• Colussi DM, Parisot CY, Lefevre GY. Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor. J Clin Pharmacol. 1998 Aug;38(8):727–735.
   PubMed Web of Science ®Google Scholar
• Pfister CU, Martoni A, Zamagni C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos. 2001 Jul;22(5):191–197.
   PubMed Web of Science ®Google Scholar
• Sioufi A, Gauducheau N, Pineau V, et al. Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos. 1997 Dec;18(9):779–789.
   PubMed Web of Science ®Google Scholar
• Haynes BP, Dowsett M, Miller WR, et al. The pharmacology of letrozole. J Steroid Biochem Mol Biol. 2003 Oct;87(1):35–45.
   PubMed Web of Science ®Google Scholar
• Grimm SW, Dyroff MC. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos. 1997 May;25(5):598–602.
   PubMed Web of Science ®Google Scholar
• Femara ® (letrozole tablets). 2022 Feb 28. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020726s014lbl.pdf
   Google Scholar
• Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Nov 6;349(19):1793–1802.
   PubMed Web of Science ®Google Scholar
• Duhan N, Madaan S, Sen J. Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women. Eur J Obstet Gynecol Reprod Biol. 2013 Dec;171(2):329–332.
   PubMed Web of Science ®Google Scholar
• Kelly CM, Buzdar AU. Anastrozole. Expert Opin Drug Saf. 2010 Nov;9(6):995–1003.
   PubMed Web of Science ®Google Scholar
• Lonning P, Pfister C, Martoni A, et al. Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol. 2003 Aug;30(Suppl 4):23–32.
   PubMed Web of Science ®Google Scholar
• Yates RA, Dowsett M, Fisher GV, et al. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer. 1996 Feb;73(4):543–548.
   PubMed Web of Science ®Google Scholar
• Yates RA, Wong J, Seiberling M, et al. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. Br J Clin Pharmacol. 2001 May;51(5):429–435.
   PubMed Web of Science ®Google Scholar
• Varelas FK, Papanicolaou AN, Vavatsi-Christaki N, et al. The effect of anastrazole on symptomatic uterine leiomyomata. Obstet Gynecol. 2007 Sep;110(3):643–649.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Scala C, Barra F. Regarding “does ulipristal acetate affect surgical experience at laparoscopic myomectomy?” J Minim Invasive Gynecol. 2018 Mar - Apr;25(3):541.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Alessandri F, Vellone VG, et al. Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study. Eur J Obstet Gynecol Reprod Biol. 2016 Oct;205:43–47.
   PubMed Web of Science ®Google Scholar
• Moravek MB, Yin P, Ono M, et al. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications. Hum Reprod Update. 2015 Jan-Feb;21(1):1–12.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Ishi K, Serna VA, et al. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010 Jun;151(6):2433–2442.
   PubMed Web of Science ®Google Scholar
• Ikhena DE, Bulun SE. Literature review on the role of uterine fibroids in endometrial function. Reprod Sci. 2018 May;25(5):635–643.
   PubMed Web of Science ®Google Scholar
• Grandi G, Barra F, Ferrero S, et al. Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care. 2019 Feb;24(1):61–70.
   PubMed Web of Science ®Google Scholar
• Dababou S, Garzon S, Lagana AS, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021 Jul 18;30(9):903–911.
   PubMed Web of Science ®Google Scholar
• Kim SM, Yoo T, Lee SY, et al. Effect of SKI2670, a novel, orally active, non-peptide GnRH antagonist, on hypothalamic-pituitary-gonadal axis. Life Sci. 2015 Oct 15;139:166–174.
   PubMed Web of Science ®Google Scholar
• Kim SM, Lee M, Lee SY, et al. Discovery of an orally bioavailable gonadotropin-releasing hormone receptor antagonist. J Med Chem. 2016 Oct 13;59(19):9150–9172.
   PubMed Web of Science ®Google Scholar
• De Milliano I, Van Hattum D, Ket JCF, et al. Endometrial changes during ulipristal acetate use: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2017 Jul;214:56–64.
   PubMed Web of Science ®Google Scholar
• Istre O. Unexpected uterine leiomyosarcoma during laparoscopic hysterectomy treated 6 months with ulipristal acetate and contained power morcellation. J Minim Invasive Gynecol. 2017 Feb;24(2):198.
   PubMed Web of Science ®Google Scholar
• Fernandez H, Schmidt T, Powell M, et al. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: premya study results. Eur J Obstet Gynecol Reprod Biol. 2017 Jan;208:91–96.
   PubMed Web of Science ®Google Scholar
• Kadhel P, Smail M, Borja De Mozota D. Inefficiency of ulipristal acetate on uterus leiomyomas as an additional sign to suspect leiomyosarcoma. J Gynecol Obstet Hum Reprod. 2017 Sep;46(7):609–611.
   PubMed Web of Science ®Google Scholar
• Nair HB, Santhamma B, Dileep KV, et al. EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model. Sci Rep. 2019 Nov 21;9(1):17279.
   PubMedGoogle Scholar
• Ferrero S, Venturini PL, Remorgida V.Letrozole monotherapy in the treatment of uterine myomas.Fertil Steril.2010May1;93(7):e31. author reply e32.
   PubMed Web of Science ®Google Scholar
• Song H, Lu D, Navaratnam K, et al. Aromatase inhibitors for uterine fibroids. Cochrane Database Syst Rev. 2013 Oct;23(10):CD009505.
   Google Scholar
• Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009.
   PubMedGoogle Scholar
• Sefton EC, Qiang W, Serna V, et al. MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth. Endocrinology. 2013 Nov;154(11):4046–4057.
   PubMed Web of Science ®Google Scholar
• Rizzello A, Franck J, Pellegrino M, et al. A proteomic analysis of human uterine myoma. Curr Protein Pept Sci. 2017;18(2):167–174.
   PubMed Web of Science ®Google Scholar
• El Sabeh M, Saha SK, Afrin S, et al. Wnt/beta-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities. Mol Cell Biochem. 2021 Sep;476(9):3513–3536.
   PubMed Web of Science ®Google Scholar
• Ono M, Yin P, Navarro A, et al. Paracrine activation of WNT/beta-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17053–17058.
   PubMed Web of Science ®Google Scholar
• Islam MS, Ciavattini A, Petraglia F, et al. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update. 2018 Jan 1;24(1):59–85.
   PubMed Web of Science ®Google Scholar